Mats Ehinger
11 – 20 of 96
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia
(
- Contribution to journal › Article
-
Mark
A Proposal for the Performance, Classification, and Reporting of Lymph Node Fine-Needle Aspiration Cytopathology : The Sydney System
(
- Contribution to journal › Article
- 2019
-
Mark
Measurable residual disease testing for personalized treatment of acute myeloid leukemia
(
- Contribution to journal › Scientific review
-
Mark
Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML
(
- Contribution to journal › Article
- 2018
-
Mark
Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow
(
- Contribution to journal › Letter
- 2017
-
Mark
Transplantation of Haploidentical TcRaß-Depleted Hematopoietic Cells Allows for Optimal Timing and Sustained Correction of the Metabolic Defect in Children With Infantile Osteopetrosis
(
- Contribution to journal › Article
-
Mark
Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing
(
- Contribution to journal › Article
-
Mark
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
(
- Contribution to journal › Article
-
Mark
Signaling via Smad2 and Smad3 is dispensable for adult murine hematopoietic stem cell function in vivo
2017) In Experimental Hematology(
- Contribution to journal › Article
- 2016
-
Mark
Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4
(
- Contribution to journal › Article